Skip to main content
. 2021 Jul 27;25(17):8087–8094. doi: 10.1111/jcmm.16798

TABLE 1.

Summary of main large‐scale clinical trials in recent years

Trail Year Patients Setting Study design Agent dose Main clinical results
LoDoCo42 2013 532 Stable CAD (n = 282), controls (n = 250) Single‐blind RCT Colchicine 0.5 mg/d In patients with stable coronary disease, low dose of colchicine (0.5 mg per d) seems to effectively prevent cardiovascular events
CANTOS40 2017 10061 MI ≥ 30 d (n = 6717), controls (n = 3344) Double‐blind, placebo controlled RCT Canakinumab 50 mg, 150 mg, 300 mg/3 mo 150 mg of Canakinumab every 3 mo resulted in a significantly lower incidence of recurrent cardiovascular events than placebo, regardless of the reduction in blood lipid levels
CIRT47 2019 4786 Resent MI (n = 2391), controls (n = 2395) Double‐blind, placebo controlled RCT Methotrexate 15–20 mg/wk Low‐dose methotrexate does not reduce IL−1β, IL−6 or C‐reactive protein levels, and does not cause fewer cardiovascular events than placebo
COLCOT48 2019 4745 Resent MI (n = 2366), controls (n = 2379) Double‐blind, placebo controlled RCT Colchicine 0.5 mg/d 0.5 mg of colchicine per day has a much lower rate of ischemic cardiovascular events than placebo
COPS45 2020 795 ACS and CAD (n = 396), controls (n = 399) Double‐blind, placebo controlled RCT Colchicine 1 mg/d for 1 mo, then 0.5 mg/day for 11 mo The addition of colchicine to standard drug therapy has no significant effect on the cardiovascular outcome of ACS patients at 12 mo and is associated with a higher mortality rate
LoDoCo243 2020 5522 Stable CAD (n = 2762), controls (n = 2760) Double‐blind, placebo controlled RCT Colchicine 0.5 mg/d Patients receiving 0.5 mg of colchicine per day had a significantly lower risk of cardiovascular events than patients receiving placebo

Abbreviations: ACS, Acute coronary syndrome; CAD, coronary atherosclerotic disease; CANTOS, Canakinumab Anti‐inflammatory Thrombosis Outcome Study; CIRT, Cardiovascular Inflammation Reduction Trial; COLCOT, Colchicine Cardiovascular Outcomes Trial; COPS, The Australian COPS Trial; LoDoCo, the Low‐dose Colchicine trail; LoDoCo2, the Low‐dose Colchicine trail 2; MI, myocardial infraction; RCT, Redis Computed Tomography.